James Crowe, Jr., MD, left, and Naveenchandra Suryadevara, PhD, have discovered a monoclonal antibody with therapeutic potential that neutralizes both RSV and hMPV. (photo by Anthony Czelusniak)

Researchers discover antibody that neutralizes both RSV and hMPV

Vanderbilt and Stanford University researchers discovered a potent, cross-neutralizing human monoclonal antibody against the respiratory syncytial virus and human metapneumovirus.

Hope for an RSV vaccine

Newly discovered features in an RSV protein may be useful for rational structure-based vaccine design.

Natural killer cells don’t clear HMPV

Understanding how the immune system responds to the respiratory virus HMPV is crucial for developing vaccines and anti-viral treatments.

Respiratory virus vaccine candidate

Virus-like particles containing a protein from human metapneumovirus are a promising vaccine candidate for this respiratory virus.

Research reveals clues to childhood respiratory virus

New Vanderbilt-led research published in the Feb. 14 issue of the New England Journal of Medicine has identified the relatively unknown human metapneumovirus (MPV) as the second most common cause of severe bronchiolitis in young children.

Cell entry ports for cold virus

The respiratory virus HMPV uses its fusion (F) protein – which interacts with cellular receptors called integrins – to bind to and enter target cells.